Skip to main content
Premium Trial:

Request an Annual Quote

Cellular Dynamics, AstraZeneca Ink Stem Cell Partnership

NEW YORK (GenomeWeb News) – Cellular Dynamics today said that it will collaborate with AstraZeneca on developing new human induced pluripotent stem cells for therapeutic discovery screening applications.

Cellular Dynamics said that under the "Center of Excellence" agreement AstraZeneca will use the firm's iCell and MyCell products for iPSC reprogramming and differentiation, and the firms will collaborate on the development of one or more novel cell types. Specifically, Cellular Dynamics said that AstraZeneca will use the MyCell technology to genetically engineer and manufacture cells from specific patient groups for use as in vitro disease models.

Cellular Dynamics CEO Bob Palay noted that the deal with AstraZeneca is the firm's third Center of Excellence agreement with a global pharmaceutical company.

Further terms of the alliance were not disclosed.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.